TITLE

The "Medicare Demo" of coverage for the MS drugs

AUTHOR(S)
Davis, Winston
PUB. DATE
April 2005
SOURCE
Inside MS;Apr-May2005, Vol. 23 Issue 2, p46
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Examines the Medicare Demo provision in the Medicare Prescription Drug, Improvement and Modernization Act of 2003 in the U.S. Amount of fund allocated to cover disease-modifying drug therapy for people with multiple sclerosis; Number of slots available in the Medicare Demo program; Cost of drugs paid by people who cannot afford the Medicare Demo deductibles.
ACCESSION #
16730548

 

Related Articles

  • Health Savings Accounts Poised to Change the Health Care Landscape. Bernardin, Margaret R.; Pearson, David A. // Venulex Legal Summaries;2003 Q4, p1 

    The article provides information on Health Savings Accounts created as part of the U.S. Medicare Prescription Drug, Improvement and Modernization Act of 2003. The objective of the said accounts is to provide individuals the ability to save for health care expenses, on a pre-tax basis, effective...

  • Medicare Reform and Health Savings Accounts: A Trojan Horse for Industry? O'Connell, Brian // BioPharm International;Apr2004, Vol. 17 Issue 4, p24 

    Focuses on the government program design to mitigate higher healthcare costs in the U.S. Provision of consumers with flexibility in managing their healthcare budgets; Impact of the Medicare reform bill on consumers, employees, and health services companies; Benefits of the prescription drug...

  • D for Doomed? Huang, Wendy; Mozeson, Mark; Pesile, Jason // Pharmaceutical Executive;May2006, Vol. 26 Issue 5, p138 

    The article provides insights on problems associated with the implementation of the Medicare Modernization Act (MMA). According to the article, the U.S. government has underestimated the expenses involved in the implementation. Results from the Wall Street Journal/Harris Online survey showed...

  • Alternative data sources for estimating multiple sclerosis prevalence. Koch-Henriksen, Nils // Multiple Sclerosis Journal;Nov2013, Vol. 19 Issue 13, p1682 

    An introduction is presented in which the editor discusses the prescription data used for disease modifying drugs against multiple sclerosis from the health authorities as prevalence estimation alternative source.

  • In the eye of the storm. Elswick, Jill // Employee Benefit News;Aug2002, Vol. 16 Issue 10, p29 

    States that pharmacy costs are the point of complaints over rising health benefit costs in the U.S. Reason for criticizing pharmaceutical companies; Concerns on the use of anti-inflammatory drugs such as Celebrex and Vioxx; Response of the Pharmaceutical Research and Manufacturers of America to...

  • Equine Opportunity? Sepkowitz, Kent // Newsweek;5/14/2012, Vol. 159 Issue 20, p12 

    The article discusses the cost of available treatments, therapies, and medication for the chronic neurologic disease multiple sclerosis.

  • Improved Adherence to Disease-Modifying Therapy Reduces Health Care Resource Use and Medical Costs. Williams, Glenn S. // Neurology Reviews;Oct2014, Vol. 22 Issue 10, p12 

    The article looks at a study which founds the improved adherence to disease-modifying therapy (DMT) reduces the medical cost, inpatient stays and the emergency visits of the patients with multiple sclerosis (MS).

  • MS drug costs -- no relief in sight.  // PharmacoEconomics & Outcomes News;10/13/2012, Issue 664, p9 

    The article discusses research on the cost of multiple sclerosis drugs which is expected to increase by 50,000 dollars by 2016, referencing a study conducted by Prime Therapeutics published in the October 4, 2012 issue of "Media Release."

  • Cost-effectiveness modeling in MS: credibility questioned.  // PharmacoEconomics & Outcomes News;Aug2015, Vol. 735 Issue 1, p10 

    The article reviews the report "Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs?" by L. Garattini et al., published in the August 21, 2015 issue of "PharmacoEconomics," which discusses economic evaluations of treatment for multiple sclerosis (MS).

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics